roll over study for patients who have completed a previous oncology study with durvalumab

Conditions: Cancer

Summary: the rationale of the rosy-d study is to continue to provide study treatment for patients who have participated in a parent study with durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the investigator.

rosy-d is an open label, non-randomised, multicentre, international trial for patients who have completed a parent study using durvalumab and who are deriving clinical benefit from continued treatment as judged by the investigator. patients will be rolled-over from the parent study and will continue the study indefinitely, until they meet one of the treatment discontinuation criteria.

Eligibility criteria:
inclusion criteria: the core protocol inclusion criteria are: * provision of signed and dated, written informed consent form (icf). * patient is currently deriving clinical benefit, as judged by the investigator, from continued treatment in an astrazeneca parent study using an astrazeneca compound that has met its endpoints, or has otherwise stopped, or the patient has reached maximum treatment duration allowed in the parent study's protocol. * patient can receive durvalumab as a fixed dose of 1500 mg quarterly 4 weeks at study entry. there are no additional inclusion criteria for the rosy-d sub-study. exclusion criteria: the core protocol exclusion criteria are. * ongoing, unresolved, grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study. * currently receiving treatment with any prohibited medication(s). * concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * permanent discontinuation from the parent study due to toxicity or disease progression (increase in the severity of the disease under study and/or increases in the symptoms of a patient's condition attributable to the disease, as assessed and documented by the investigator. physician-defined progression can be radiological \[example: response evaluation criteria in solid tumours\] progression or clinical progression). * local access to commercially-available drug at no cost to the patient as permitted by local/country regulation. the additional exclusion criteria for the rosy-d sub-study are: * active infection including coronavirus disease 2019 (polymerase chain reaction confirmed and/or clinically suspected), tuberculosis, hepatitis b (known positive hepatitis b virus (hbv) surface antigen result), hepatitis c, or human immunodeficiency virus (hiv) (positive hiv 1/2 antibodies). * male or female patients of reproductive potential who are not willing to employ effective birth control from study inclusion up to 90 days after the last dose of durvalumab monotherapy. * ongoing, unresolved, grade 2 toxicity with an inability to reduce corticosteroid to a dose of ≤ 10 mg of prednisone per day (or equivalent) within 12 weeks after last dose of study treatment/study regimen, per toxicity dose modification and tmgs for immune- mediated, infusion-related, and non-immune-mediated reactions guidelines of the parent study.

Keywords: cancer oncology clinically benefit roll over study durvalumab